Jazz Pharmaceuticals

Kickback Allegation Settlements Pile Up for Pharmaceutical Companies
Kickback Allegation Settlements Pile Up for Pharmaceutical Companies
RAPS.org
kickbacks
Medicare
physicians
Pfizer
Jazz Pharmaceuticals
Valeant Pharmaceuticals
Shire
Omnicare
Flag link:
Sparks sells regulatory fast pass to Jazz for $110M
Sparks sells regulatory fast pass to Jazz for $110M
Biopharma Dive
Spark Therapeutics
Jazz Pharmaceuticals
priority review vouchers
Flag link:
Jazz, ImmunoGen partner on hematology, oncology drug development
Jazz, ImmunoGen partner on hematology, oncology drug development
BioPharma Dive
Jazz Pharmaceuticals
Immunogen
oncology
hematology
drug development
Flag link:
FDA approves Jazz Pharmaceuticals’ liposomal AML chemotherapy
FDA approves Jazz Pharmaceuticals’ liposomal AML chemotherapy
Drug Delivery Business News
FDA
Jazz Pharmaceuticals
liposomal chemotherapy
Vyxeos
AML
Flag link:
Jazz nabs early FDA nod for AML med Vyxeos. Is diversifying M&A next?
Jazz nabs early FDA nod for AML med Vyxeos. Is diversifying M&A next?
Fierce Pharma
Jazz Pharmaceuticals
FDA
AML
Vyxeos
M&A
Flag link:
Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul
Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul
Bloomberg
rare disease
healthcare reform
Shire
Jazz Pharmaceuticals
Sanofi
Roche
Biogen
Alexion
Vertex Pharmaceuticals
Flag link:
Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round
Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round
Endpoints
oncology
PARP inhibitors
2X Oncology
Eisai
2X-121
Jazz Pharmaceuticals
Flag link:
3 Reasons Jazz Pharmaceuticals Stock Could Fall
3 Reasons Jazz Pharmaceuticals Stock Could Fall
Motley Fool
Jazz Pharmaceuticals
Vyxeos
Xyrem
Flag link:
Jazz hits a nigh note with positive narcolepsy results
Jazz hits a nigh note with positive narcolepsy results
BioPharma Dive
Jazz Pharmaceuticals
narcolepsy
JZP-110
Flag link:
Jazz Pharmaceuticals stock surges 7% on settlement with Hikma over generic drug
Jazz Pharmaceuticals stock surges 7% on settlement with Hikma over generic drug
Marketwatch
Jazz Pharmaceuticals
Hikma
generics
Xyrem
narcolepsy
Flag link:
Jazz beats 4Q profit forecasts
Jazz beats 4Q profit forecasts
Yahoo/AP
earnings
Jazz Pharmaceuticals
Flag link:
Top 25 rare disease brands, by sales
Top 25 rare disease brands, by sales
Medical Marketing and Media
rare disease
Copaxone
Teva Pharmaceutical
Avonex
Biogen
Sensipar
Soliris
Alexion
Xyrem
Jazz Pharmaceuticals
Flag link:
3 Biotechs Likely to Be Acquired in 2017
3 Biotechs Likely to Be Acquired in 2017
Motley Fool
M&A
Clovis Oncology
Intercept Pharma
Jazz Pharmaceuticals
Flag link:
FDA approves generic version of Jazz Pharma's sleep disorder drug
FDA approves generic version of Jazz Pharma's sleep disorder drug
Yahoo/Reuters
FDA
generics
Jazz Pharmaceuticals
Xyrem
narcolepsy
Flag link:
Jazz misses Street 3Q forecasts
Jazz misses Street 3Q forecasts
Yahoo/AP
Jazz Pharmaceuticals
earnings
Flag link:
3 Hottest Cancer Biotech Acquisition Targets After Medivation
3 Hottest Cancer Biotech Acquisition Targets After Medivation
Forbes
cancer
biotech
M&A
Puma Biotechnology
Jazz Pharmaceuticals
Kite Pharma
Flag link:
Jazz misses Street 2Q forecasts
Jazz misses Street 2Q forecasts
Yahoo/AP
Jazz Pharmaceuticals
earnings
Flag link:
With new additions, PhRMA opens door to generics drugmaker Teva
With new additions, PhRMA opens door to generics drugmaker Teva
BioPharma Dive
PhRMA
generics
Teva Pharmaceuticals
Alexion
Amag Pharmaceuticals
Horizon Pharma
Jazz Pharmaceuticals
Flag link:
Jazz Pharmaceuticals: How Much Return Potential Does It Have?
Jazz Pharmaceuticals: How Much Return Potential Does It Have?
Market Realist
Jazz Pharmaceuticals
Flag link:
A Look at Jazz Pharmaceuticals’ Celator Acquisition Deal
A Look at Jazz Pharmaceuticals’ Celator Acquisition Deal
Market Realist
Jazz Pharmaceuticals
Celator
M&A
Flag link:

Pages